 Based on interim pharmacokinetics PK results from the ongoing multiple ascending dose study Liminal BioSciences Inc NASDAQ: LMNL has decided not to move fezagepras into a Phase 2 study in Idiopathic Pulmonary Fibrosis and a Phase 1a2b study in Hypertriglyceridemia. The Company is evaluating the interim PK results. 